期刊文献+

化疗药物敏感和耐药试验在卵巢癌中的研究现状 被引量:4

下载PDF
导出
摘要 化疗药物敏感和耐药试验是近几十年发展起来的一种新技术,主要包括四甲基偶氮唑盐比色法、三磷酸腺苷-肿瘤药物敏感试验、ChemoFx、极端耐药试验等十几种方法,这些方法各有所长;尽管通过多年的研究,国内外学者在CSRA试验结果与卵巢上皮癌临床治疗结果的一致性方面、CSRA指导治疗与经验治疗的疗效对比方面,仍存在一定争议,需要前瞻性大样本随机对照研究确定CSRA在临床应用方面的价值。
出处 《癌症进展》 2013年第4期292-296,共5页 Oncology Progress
基金 北京市科学技术委员会"北京医药产品和技术重大项目培育研究"专项资助课题(Z101107050210028)
  • 相关文献

参考文献22

  • 1Fruehauf JP, Alberts DS. In vitro drug resistance versus chemosensitivity: two sides of different coins [ J]. J Clin Oncol, 2005, 23 (15):3641 -3643. 被引量:1
  • 2Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures [ J ]. J Natl Cancer Inst, 1990, 82 (7):582-588. 被引量:1
  • 3Cree IA. Chemosensitivity and chemoresistance testing in ovarian cancer [J]. Curt Opin Obstet Gynecol, 2009, 21 (1):39 -43. 被引量:1
  • 4Burstein H J, Mangu PB, Somerfield MR, et al. American Society of Clinical Oncology clinical practice guideline up- date on the use of chemotherapy sensitivity and resistance assays [J]. J Clin Oncol, 2011, 29 (24):3328-3330. 被引量:1
  • 5Konecny G, Crohns C, Pegram M, et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage Ⅱ ovarian cancer [ J ]. Gynecol On- col, 2000, 77 (2):258-263. 被引量:1
  • 6Neubaner H, Stefanova M, Solomayer E, et al. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian canc- er [J]. Anticancer Res, 2008, 28 (2A): 949-955. 被引量:1
  • 7赵丹,吴令英,李晓光,王小兵,李莱,李艳芬,田海梅,宋培培,刘静,常青云,张伟.三磷酸腺苷-肿瘤体外药敏试验预测复发性卵巢上皮癌化疗敏感性的价值[J].中华肿瘤杂志,2010,32(11):855-858. 被引量:6
  • 8赵丹,吴令英,王小兵,李晓光,李茉,李艳芬,田海梅,张伟.三磷酸腺苷-肿瘤体外药敏试验在预测原发性卵巢上皮癌化疗敏感性中的应用价值[J].中华肿瘤杂志,2010,32(5):368-372. 被引量:11
  • 9Kurbacher CM, Cree IA, Bruckner HW, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer [ J]. Anticancer Drugs, 1998, 9 (1):51 -57. 被引量:1
  • 10Sharma S, Neale MH, Di Nicolantonio F, et al. Outcome of ATP-based tumor chemosensitivity assay directed chemo- therapy in heavily pre-treated recurrent ovarian carcinoma [J]. BMC Cancer, 2003, 3 : 19. 被引量:1

二级参考文献20

  • 1田海梅,石晓燕,傅军,曹冬艳,张凯,吴令英,王金万,张伟.ATP抗肿瘤药物敏感性检测技术与卵巢癌临床治疗的相关性研究[J].中华肿瘤杂志,2005,27(5):296-298. 被引量:17
  • 2张伟.生物荧光肿瘤体外药敏检测技术的临床应用[J].中华检验医学杂志,2005,28(12):1316-1319. 被引量:9
  • 3Sevin BU,Peng ZL,Perns JP,et al.Application of an ATP-biolumin-escence assay in human tumor chemosensitivity testing.Cynecol Oncol,1988,31:191-204. 被引量:1
  • 4Kurbacher CM,Cree IA,Bruckner HW,et al.Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer.Anticancer Drugs,1998,9:51-57. 被引量:1
  • 5Sharma S,Neale MH,Di Nicolantonio F,et al.Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.BMC Cancer,2003,3:19. 被引量:1
  • 6Cree IA,Kurbacher CM,Lamont A,et al.A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.Anticancer Drugs,2007,18:1093-1101. 被引量:1
  • 7Konecny C,Crohns C,Pegram M,et al.Correlation of drug response with the ATP tumorchemosensitivity assay in primary F1GO stage Ⅲ ovarian cancer.Gynecol Oncol,2000,77:258-263. 被引量:1
  • 8Neubauer H,Stefanova M,Solomayer E,et al.Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.Anticancer Res,2008,28:949-955. 被引量:1
  • 9Inciura A,Simavicius A,Juozaityte E,et al.Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer:a retrospective study of 574 patients.BMC Cancer,2006,6:153. 被引量:1
  • 10Bristow RE,Chi DS.Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer:a meta-analysis.Gynecol Oncol,2006,103:1070-1076. 被引量:1

共引文献13

同被引文献52

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部